Rationale documents and publications

EUCAST public consultations

Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Comments not entered into the designated document will not be considered (download form for comments).

 

Current public consultations (use this form for comments).

 

  • The (preliminary) breakpoint table for 2025 (v.15.0) is available for consultation (5 Dec - 16 Dec).
    • Breakpoint table v 15.0 (for screen). The consultation is primarily to (1) help with proof reading and error detection, (2) to give everyone a heads-up in time for the formal publiction of the new table 1 Jan, 2025. The consultation is not for consultation on individual breakpoints - this will have been dealt with in "Public consultations" over the last 12 months. For new ideas, conflicting opinions etc, contact EUCAST via your NAC or directly the chair or the webmaster. Comments are submitted via: the form for comments.
      The following merits highlighting:
      • Breakpoints for cefepime-enmetazobactam and aztreonam-avibactam formally added to the table (during 2024 available as addenda)
      • Endocarditis breakpoints added (where these differ from general breakpoints, this is clearly marked in the new breakpoint table). A guidance document on the reporting of susceptibility tests in endocarditis pathogens is released simultaneously.
      • Information on additional agents for Stenotrophomonas maltophilia added (see also the new guidance document)
      • Revised breakpoints for benzylpenicillin vs. Streptococcus groups A, B, C and G, Streptococcus pneumoniae and viridans group streptococci.
      • New testing algorithm with oxacillin and benzylpenicillin to categorise benzylpenicillin in S.pneumoniae without MIC testing.
      • Information on EUCAST breakpoints and dosing for challenging infection sites and on special situations for antimicrobial treatment added

 

Upcoming public consultations:

 

  • Nocardiae spp - breakpoints and MIC/Zone diameter distributions and criteria. 
  • A version of the EUCAST dosing table relevant for children, is under preparation.
  • Each year EUCAST publishes a preliminary "next breakpoint table" to allow colleagues to help us find editorial errors and to familiarize themselves with the new table. This is some weeks before the publication of the new table on the 1st of January. It is not a consultation on changes in breakpoints or guiding “Notes”. These have been preceded by longer periods of consultation during the year.

 

Previous public consultations with comments and EUCAST responses:

 

 

Comments not entered into the designated document (Document for comments) will not be considered.